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Ethical issues 
 
The development of new, sensitive and reliable bio-markers 
requires the utilisation of human tissue for research purposes 
and although such uses may be regarded as long established 
and routine, there have been a number of incidents which have 
brought such practices under scrutiny. The case of Moore 
against the University of California raised the question of 
whether the body and its parts could be regarded as property 
and thus entitle donors to share in any financial benefit.  In the 
UK, the scandal of Bristol/Alder Hey exposed the culture within 
medicine of presuming a right to procure and utilise human 
tissues without consent and the more recent controversy over 
the Myriad Company’s claimed monopoly on the tests for 
BRCA1/2 has caused bitter resentment amongst patient groups, 
clinicians and  researchers. 
Ethical issues in bio-marker research 
 
Simon Woods, Pauline McCormack - Policy, Ethics & Life Science (PEALS), Newcastle University 
simon.woods@ncl.ac.uk 
 
  
 
 
Biomarkers in Neuromuscular Disorders (NMDs) 
 
Rapidly expanding knowledge of NMDs has provided new targets 
for disease characterisation, early diagnosis and drug 
development whilst presenting many challenges about how to 
translate this knowledge into clinical practice. 
  
Omic sciences are used to identify non-invasive biomarkers 
which offer an invaluable tool for monitoring disease 
progression, prognosis and response to drug treatment during 
clinical trials. Biomarkers represent excellent substitutes for 
clinical endpoints because they can predict a clinical benefit 
more quickly than other measures and in a less invasive way 
than muscle biopsies. 
 
 
Discussion 
 
Ethical concerns associated with autonomy, include consent and 
withdrawal from research, as well as issues of confidentiality.  
Such issues are particularly complex in genetic research. Within 
the BIO-NMD project it was recognised that it was important to 
ensure patients understood how their samples were going to be 
used and made available (or not) for wider research.  
  
Governance and Stewardship 
Studies that involve scrutiny of DNA are likely to encounter 
unintended consequences by discovering anomalies within their 
‘findings’. There is some consensus that incidental findings (IFs) 
of clinical significance impose a duty on the researcher to disclose 
such findings, although the debate is on-going. Studies must 
have an appropriate plan for whether and how to reveal IFs to 
the tissue donors or their physicians.  BIO-NMD adopted a 
flexible approach to this as there is as yet no international 
consensus on which ethical approach to use. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Benefit sharing 
Any research may provide an opportunity for profit and there has 
been wide debate as to whether profiting from research which 
involves patients’ tissues and their wider collaboration is itself 
ethical.  
 
The approach taken in the BIO-NMD project is one that fits with a 
more altruistic conception of benefit sharing. On this model 
patient involvement in research, including use of tissue is 
regarded as a donation freely given over to good governance and 
the stewardship of the researchers, on the principle that benefit 
in kind will be available to the patient and the disease 
community. 
 
Future Challenges 
As genetic research becomes ever more sophisticated with the 
pooling and sharing of data and tissue the ethics, governance, 
and regulation of research must keep pace. Keeping an open 
dialogue between researchers and patients that is based upon 
transparency and trust will make an important contribution to the 
process of change. 
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